GLUCOTROL XL Drug Patent Profile

Which patents cover Glucotrol Xl, and what generic alternatives are available?

Glucotrol Xl is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in GLUCOTROL XL is glipizide. There are eighteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the glipizide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glucotrol Xl

A generic version of GLUCOTROL XL was approved as glipizide by AUROBINDO PHARMA USA on May 10^th, 1994.

Summary for GLUCOTROL XL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	98
Clinical Trials:	15
Patent Applications:	4,267
Drug Prices:	Drug price information for GLUCOTROL XL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GLUCOTROL XL
What excipients (inactive ingredients) are in GLUCOTROL XL?	GLUCOTROL XL excipients list
DailyMed Link:	GLUCOTROL XL at DailyMed

See drug prices for GLUCOTROL XL

See drug sales revenues for GLUCOTROL XL

Recent Clinical Trials for GLUCOTROL XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Memorial Sloan Kettering Cancer Center	Phase 2
Baylor College of Medicine	Phase 4
Novartis	Phase 2

See all GLUCOTROL XL clinical trials

Pharmacology for GLUCOTROL XL

Drug Class

Sulfonylurea

US Patents and Regulatory Information for GLUCOTROL XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-003	Aug 10, 1999		DISCN	Yes	No
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-001	Apr 26, 1994	AB	RX	Yes	No
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994	AB	RX	Yes	No

Expired US Patents for GLUCOTROL XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-001	Apr 26, 1994	5,024,843
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994	4,612,008
Pfizer	GLUCOTROL XL	glipizide	TABLET, EXTENDED RELEASE;ORAL	020329-002	Apr 26, 1994	5,591,454

International Patents for GLUCOTROL XL

See the table below for patents covering GLUCOTROL XL around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0490991	DOSAGE FORM FOR ADMINISTERING ORAL HYPOGLYCEMIC GLIPIZIDE
Germany	69003392
Austria	A88084

Market Dynamics and Financial Trajectory for Glucotrol XL

Last updated: July 29, 2025

---

Introduction

Glucotrol XL (generic name: glipizide extended-release) serves as a cornerstone in the management of type 2 diabetes mellitus. Since its FDA approval, Glucotrol XL has established a significant position within the fiercely competitive antidiabetic drug market. Understanding the current market dynamics and forecasting its financial trajectory necessitates examining its clinical profile, competitive landscape, regulatory environment, and emerging market opportunities.

---

Clinical Profile and Therapeutic Positioning

Glucotrol XL's extended-release formulation offers improved glycemic control with once-daily dosing, enhancing patient adherence compared to immediate-release counterparts. As a sulfonylurea, it stimulates pancreatic insulin secretion, primarily benefiting patients with early-stage, insulin-deficient type 2 diabetes. Its well-characterized safety profile, including a risk of hypoglycemia and weight gain, remains a pertinent consideration.

Market Overview

Global Market Size and Segmentation

According to global market research (e.g., MarketsandMarkets, 2022), the global antidiabetic drug market was valued at approximately $58 billion in 2022, projected to grow at a CAGR of 8% through 2030. Glucotrol XL contributes a sizeable share within the sulfonylurea segment, with a sizeable branded and generic market presence across North America, Europe, and emerging markets.

Competitive Landscape

The competitive landscape encompasses:

• Brand vs. generic: While Pfizer originally marketed Glucotrol XL, multiple generics now dominate the market, exerting downward pressure on pricing.
• Alternative drug classes: DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin therapies are increasingly favored due to lower hypoglycemia risks and additional benefits like weight loss. However, sulfonylureas like Glucotrol XL retain relevance in cost-sensitive populations and regions.

Key Market Drivers

• Cost Effectiveness: As one of the more affordable therapies, Glucotrol XL appeals to markets with limited healthcare budgets.
• Growing Prevalence: Rising type 2 diabetes prevalence, driven by obesity and aging populations, sustains demand.
• Improved Formulation: Extended-release formulations improve compliance and reduce adverse effects, supporting steady sales.

---

Regulatory and Patent Landscape

Patent Expiry and Generic Competition

Patent expiration of the original formulation (Pfizer’s patent expired around 2011-2015) has led to a proliferation of generic versions, intensifying price competition. Today, multiple generics share market dominance, impacting brand profitability.

Regulatory Considerations

FDA and EMA continue to monitor safety signals, including hypoglycemia risks. Recent guidelines favor individualized therapy, influencing prescribing patterns.

---

Market Challenges and Opportunities

Challenges

• Market Shrinkage: Brand erosion due to generics and clinician preference for newer agents.
• Safety Concerns: Risks of hypoglycemia and cardiovascular issues influence prescribing limits.
• Insurance Coverage: Reimbursement policies increasingly favor newer drug classes offering additional benefits, potentially limiting sulfonylurea adoption.

Opportunities

• Emerging Markets: Low-cost positioning aligns with healthcare expansion in Asia, Africa, and Latin America.
• Combination Therapy: Fixed-dose combinations incorporating glipizide with metformin or other agents enhance adherence.
• New Formulations: Investigating novel formulations for improved safety and efficacy.

---

Financial Trajectory

Revenue Trends and Forecasts

Historically, Glucotrol XL’s revenues peaked pre-generic entry, with Pfizer reporting approximately $300 million annually in the United States before patent expiry. Post-patent, revenues have declined sharply due to generic competition but stabilize through:

• Volume growth in emerging markets
• Increased prescription of cost-effective diabetes treatments
• Expanding indications for combination therapies

Forecasts suggest a gradual decline in standalone Glenzyl sales in developed markets but potential growth in volume-driven sales in low-income regions.

Pricing Dynamics

Given the commodification post-generic entry, unit prices have plummeted, with many markets witnessing price reductions exceeding 70%. This trend influences profit margins but sustains market share volume.

Strategic Positioning

Pharmaceutical companies emphasizing lifecycle management—such as reformulations, fixed-dose combinations, or new formulations—may mitigate revenue declines and open new markets.

---

Future Outlook

As the global diabetes burden intensifies, legacy drugs like Glucotrol XL, despite competitive pressures, retain value, especially in underserved populations. The key to sustaining revenue streams lies in strategic market segmentation, cost-effective manufacturing, and innovation to differentiate offerings.

Emerging focus areas such as biosimilars, digital health integration, and personalized medicine provide avenues for extending Glucotrol XL’s commercial relevance. Notably, regulatory pathways for biosimilars or fixed-dose combinations will influence its trajectory.

---

Key Market Drivers for Investment

• The ongoing diabetes epidemic assures baseline demand.
• Cost sensitivity ensures sulfonylureas remain relevant, especially in low- and middle-income countries.
• Innovation in formulation and delivery can restore market share amid modern therapies.
• Geographic expansion into emerging markets presents growth opportunities.

---

Key Takeaways

• Market Decline Mitigated by Volume: Despite patent expiry and generic competition, increased prescription volumes in emerging markets and brand loyalty sustain revenue streams.
• Pricing and Reimbursement: Price reductions constrain profit margins but open access in cost-sensitive regions.
• Competitive Pressure and Innovation: Emphasis on fixed-dose combinations and improved formulations can prolong product lifecycle.
• Regulatory Environment: Evolving safety standards and guidelines influence prescribing and market acceptance.
• Strategic Focus: Diversification through combination therapies and international expansion remains crucial for future growth.

---

FAQs

1. How has patent expiry affected Glucotrol XL’s market share?
Patent expiry led to widespread generic competition, substantially reducing branded sales—Pfizer reported a decline from approximately $300 million annually pre-expiration to lower volumes. The market shift has emphasized price competition and volume growth, especially in emerging markets.

2. What are the main alternatives to Glucotrol XL in diabetes management?
Modern therapies include DPP-4 inhibitors (e.g., sitagliptin), SGLT2 inhibitors (e.g., empagliflozin), GLP-1 receptor agonists (e.g., semaglutide), and insulin regimens—many offering better safety profiles but at higher costs.

3. Can Glucotrol XL recover market share through innovation?
Yes. Strategies such as fixed-dose combination formulations and extended-release improvements, along with targeted marketing in emerging markets, can sustain or grow its market presence.

4. What role do emerging markets play in Glucotrol XL’s future?
Emerging markets are vital, owing to their large diabetic populations and price sensitivity. Affordable formulations and expanding healthcare infrastructure enable long-term growth prospects.

5. How are safety concerns influencing Glucotrol XL’s market?
Hypoglycemia risk limits use in some populations. Regulatory bodies emphasize safety, leading to cautious prescribing, especially in elderly patients. However, proper patient education and newer formulations mitigate these effects.

---

References

1. MarketsandMarkets. (2022). Diabetes Care Drugs Market.
2. FDA. (2015). Patent and Exclusivity Data for Glipizide Extended-Release.
3. IQVIA. (2022). Active Ingredient Market Share Reports.
4. American Diabetes Association. (2022). Standards of Medical Care in Diabetes.
5. European Medicines Agency. (2021). Safety updates and guidelines on sulfonylureas.

---